Skip to main content

Table 3 Radiographic changes from baseline after 2 years of treatment

From: Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study

 

MTX (n = 37)

TwHF (n = 34)

MTX + TwHF (n = 38)

P

JE at baseline (range 0–280)

    

mean (SD)

16.76 (22.56)

20.83 (29.02)

14.92 (21.26)

 

median (IQR)

7.25 (2.00, 25.00)

7.00 (2.75, 27.00)

5.00 (2.75,15.50)

0.589

JSN at baseline (range 0–168)

    

mean (SD)

11.92 (15.35)

13.05 (16.18)

12.34 (16.06)

 

median (IQR)

6.25 (0, 17.50)

3.00 (0.75, 30.75)

5.00 (1.25, 21.00)

0.957

TSS at baseline

    

mean (SD)

28.68 (35.54)

33.88 (42.97)

26.99 (35.81)

 

median (IQR)

14.75 (2.75, 42.13)

15.00 (5.00, 47.00)

14.5 (5.00, 35.25)

0.738

Estimated annual radiographic progression at baseline†

    

mean (SD)

20.96 (78.12)

13.02 (15.07)

10.84 (15.90)

 

median (IQR)

5.74 (1.88, 10.21)

6.25 (3.51, 20.17)

5.61 (2.25, 10.37)

0.635

mTSS at 2 years

    

mean (SD)

31.94 (37.54)

36.57 (44.04)

30.21 (35.99)

 

median (IQR)

15.25 (3.94, 42.00)

18.00 (5.50, 51.67)

15.71 (7.41, 38.81)

0.826

ΔmJE

    

mean (SD)

1.59 (4.43)

1.33 (2.03)

1.44 (3.22)

 

median (IQR)

0 (0, 1.21)

0.75 (0, 2.32)

0.77 (0, 1.50)

0.939

ΔmJSN

    

mean (SD)

1.67 (3.32)

1.31 (2.41)

1.78 (3.24)

 

median (IQR)

0 ( 0, 1.13)

0 (0, 1. 52)

0 (0, 2.19)

0.781

ΔmTSS

    

mean (SD)

3.24 (6.95)

2.70 (3.70)

3.22 (5.66)

 

median (IQR)

0.61 (0,4.18)

1.00 (0,4.14)

1.04 (0,3.62)

0.862

ΔmTSS <0.5

17 (45.95%)

12 (35.29%)

13 (34.21%)

0.520

ΔmTSS ≤SDD (5.24)

31 (83.78%)

27 (79.41%)

31 (81.58%)

0.893

ΔmJE ≤SDD (3.37)

32 (86.49%)

31 (91.18%)

35 (92.11%)

0.691

ΔmJSN ≤SDD (2.85)

30 (81.08%)

27 (79.41%)

31 (81.58%)

0.955

  1. MTX methotrexate, TwHF Tripterygium wilfordii Hook F, JE joint erosion, JSNjoint space narrowing, TSS total Sharp score, mTSS modified total Sharp score, SSD smallest detectable difference
  2. Data are presented as mean (standard deviation, SD) and median (interquartile range, IQR)
  3. The p values were calculated using analysis of variance for baseline scores, while comparison for estimated progression and scores at year 2 was performed using analysis of covariance with baseline score as a covariate. Comparison of the change in score <0.5 or equal to or less than the smallest detectable difference was conducted using the χ2 test
  4. †Estimated annual radiological progression at baseline was defined as the baseline mTSS score divided by disease duration for each patient
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us